Lupin launches moxifloxacin ophthalmic solution

| Updated on February 14, 2020

Lupin has launched moxifloxacin ophthalmic solution USP, 0.5%, having received approval from the United States Food and Drug Administration earlier. The product would be manufactured at Lupin's Pithampur (Unit-II) facility, it said. The solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution had an annual sales of approximately $10 million in the US (IQVIA MAT December 2019). Shares of drug maker Lupin closed 2 per cent higher at ₹717.85 on the BSE.

Published on February 14, 2020

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor